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ABSTRACT
Gaucher disease is a rare autosomal recessive
disorder of glycosphingolipid metabolism
resulting from deficient activity of the
lysosomal enzyme beta-glucocerebrosidase
that causes accumulation of glucosylceramide
in tissue macrophage with damage to
hematological, visceral, and skeletal organ
systems. Severity and progression may vary
independently among these domains,
necessitating individualized therapy. Skeletal
involvement is highly prevalent and often
associated with intense pain, impaired
mobility, and reduced quality of life. Enzyme
replacement therapy improves parameters in all
affected domains, but skeletal involvement
requires longer treatment and higher dosages
to obtain significant results. Despite numerous
papers on bone complications in patients with
Gaucher disease, there are no specific
indications on how to assess properly bone
involvement in such condition, the frequency
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of assessment, the use of markers for osteoblast
and osteoclast activity, or the administration of
bisphosphonates or other symptomatic drugs in
adult and pediatric patients. Starting from a re-
evaluation of cases with bone involvement, we
have identified some common errors in the
diagnostic approach and management. The aim
of this paper was to propose a methodological
and critical approach to the diagnosis, follow-
up and treatment of bone disease in patients
with Gaucher disease type 1.
Keywords: Bone; Gaucher disease; Dual energy
X-ray absorptiometry; Magnetic resonance
imaging; MRI; Skeletal disease
INTRODUCTION
Gaucher disease (GD; OMIM #230800) is a
rare autosomal recessive hereditary disorder
of glycosphingolipid metabolism resulting
from deficient activity of the lysosomal
enzyme b-glucocerebrosidase (EC 3.2.1.45;
lysosomal glucocerebrosidase). Glucosylceramide
accumulates in macrophages (Gaucher cells) in
the spleen, liver, and bone marrow. Although
GD has a continuous spectrum of severity, it is
traditionally classified into three forms: type 1
(chronic; lacking early onset neuronopathy),
type 2 (acute; with early onset neuronopathy),
and type 3 (chronic; with early onset
neuronopathy) [1]. Type 1 GD accounts for
the vast majority of cases, with an incidence of
approximately 1/40–60,000 in the general
population [2, 3] and 1/500 in the Ashkenazy
population [4].
GD type 1 is a chronic multi-organ disorder
with a variety of signs and symptoms
that include hepatomegaly, splenomegaly,
(pan)cytopenia, pulmonary disease, and various
bone manifestations. The severity and clinical
course of the disease are extremely
heterogeneous, varying between patients and
affected domains in the same patient [1]. Bone
pathology in GD affects both the marrow
and structural compartments, although
the precise pathophysiological mechanisms are
not yet well understood. Bone marrow
infiltration by Gaucher cells may cause vascular
occlusion, ischemia, and compression, whereas
mineralization defects may result from abnormal
bone remodeling [1]. Skeletal manifestations are
the most disabling long-term complication of
GD, and more than 80% of patients have signs of
bone involvement at diagnosis [5, 6]. These may
include abnormal bone remodeling, osteopenia,
lytic lesions, pathological fractures, vertebral
collapse, and avascular osteonecrosis—
particularly at the femoral or humeral heads—
with possible bone collapse and joint
involvement [7]. Osteopenia is common in
patients with GD, and often occurs early in life,
resulting in reduced bone mineral density (BMD)
with lower peak bone mass and increased risk of
complications associated with bone fragility [8].
Skeletal involvement is a compelling
indication for enzyme replacement therapy
(ERT) and some bone parameters are key
treatment goals [8, 9]. While patients with
bone pain and bone crisis resulting from bone
marrow infiltration generally respond to ERT
within 2 years [10], improvement of bone
mineral density (BMD) is markedly dose-
dependent and requires up to 8 years of high-
dosage therapy to normalize [11]. Some bone
manifestations are irreversible [12]; thus, early
and sustained treatment is critical. Adequate
treatment is especially important during
adolescence and early adulthood, when peak
bone mass is accrued [13]. Moreover, early
treatment may reduce the risk of avascular
bone necrosis [14]. Over time, impaired
quality of life (QoL) may become refractory to
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therapy due to the occurrence of permanent
bone sequelae and the need for joint
replacements [15, 16].
Guidelines have been elaborated for
the diagnosis, treatment and follow-up of
patients with GD [17, 18]; however, detailed
information on the correct evaluation and
interpretation of skeletal involvement are
lacking. The aim of this paper was to propose
a methodological and critical approach to the
diagnosis, follow-up, and treatment of bone
disease in patients with GD type 1.
METHODS
To address the unmet need for improving the
approach to bone disease in GD, a panel of
physicians with experience in GD diagnosis
and treatment, as well as an expert on bone
disease, convened three times to review the
literature, discuss clinical cases of GD with
various forms and presentations of bone
involvement, and formulate recommendations
for diagnosing, monitoring, and treating
skeletal manifestations of GD. Starting from a
re-evaluation of cases with bone involvement,
we have identified some common errors in the
diagnostic approach and management.
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
CASE REPORTS
Three cases of GD are presented to illustrate
situations encountered in clinical practice;
several common pitfalls are highlighted
(Supplement 1). Suboptimal outcomes in these
clinical cases can be attributed to (a) late
diagnosis of GD, (b) the improper use
or interpretation of imaging methods for
the diagnosis and monitoring of skeletal
involvement, or (c) inadequate ERT dosage.
Based on these observations we reconsider the
most important methods for evaluating bone
disease in GD and make critical suggestions for
their use and interpretation in light of recent
advances in osteoporosis.
DISCUSSION
Imaging Methods for Assessing Bone
Damage
Dual Energy X-ray Absorptiometry (Table 1)
The gold standard for quantitative assessment
of bone mineral status in adults is dual energy
X-ray absorptiometry (DXA), performed at the
lumbar spine (L1–L4) and hip (total hip or
femoral neck). In children, in addition to DXA
performed on the L1–L4 lumbar vertebrae, scans
of the total body less head (TBLH) are
mandatory, whereas measurement of BMD at
the femur is not recommended due to high
variability in skeletal maturity [19]. The
parameters obtained from these measurements
are bone mineral content (BMC) in grams, area
in cm2, and BMD in g/cm2. Because of the two-
dimensional nature of DXA, measurements are
strongly influenced by bone size, skeletal
maturity, and pubertal stage. Small bones may
lead to an underestimation of BMD. Other
confounding factors include avascular necrosis
of the proximal femur and vertebral fractures,
which may provide misleading results. In
adults, the presence of osteophytes, vascular
calcifications, and calculi can lead to
overestimation of bone mass.
The reference DXA parameter for
premenopausal women, for men younger than
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50 years old, and for the pediatric population
is the Z-score, which refers to the mean BMD
of the subject compared to a population of
similar age, sex, and ethnicity [20]. In
the aforementioned populations, DXA
measurements with a Z-score less than or
equal to -2.0 should be reported as ‘‘BMC or
BMD below the expected range for
chronological age’’ and not with the term
‘‘osteopenia’’ [21], whereas the diagnosis of
osteoporosis should not be based only on
BMD values. For postmenopausal women and
men aged C50 years, the preferred parameter is
the T-score, which expresses BMD compared to
that of young adults (aged 20–29 years) of the
same sex. It should be interpreted according to
the World Health Organization densitometric
classification, in which a T-score between -1.0
and -2.5 indicates osteopenia, while a T-score
less than -2.5 indicates osteoporosis.
How to Perform DXA Measurement of BMD at
the lumbar spine should be performed in the
anteroposterior projection, considering the
mean BMD of at least two vertebrae among
L1–L4, excluding any vertebrae with defects or
artifacts. The femoral neck or total hip is the
optimal site for fracture risk assessment [22]. In
certain circumstances (e.g., for very obese
patients or the presence of bone damage in
Table 1 Key points for using dual energy X-ray absorptiometry (DXA) for diagnosis and follow-up in patients with
Gaucher disease (GD)
Procedure
The essential parameters are bone mineral content in grams, bone area (cm2), and bone mass density (BMD) (g/cm2)
Serial measurements of BMD should be performed with the same equipment and, if possible, by the same operator
Sites to examine
Lumbar spine (L1–L4)
Total body less head (TBLH)
Proximal femur (total hip and femoral neck)
When these sites cannot be measured, the distal third of the radius of the non-dominant forearm is evaluated
Interpretation
DXA should be interpreted using the Z-score as a reference value. Z-scores below -2.0 indicate reduced bone mineral
density. In postmenopausal women and in men aged C50 years the T-score is interpreted using the World Health
Organization (WHO) classiﬁcation for osteopenia/osteoporosis, considering methodological precision and least
signiﬁcant change detectable
Frequency
DXA should be performed at baseline and after 12 months in untreated asymptomatic patients and in patients who have
not reached therapeutic goals on enzyme replacement therapy (ERT). When therapeutic goals are achieved, the
guidelines recommend follow-up every 12–24 months. However, in our experience this can be carried out every
36 months, in the absence of inter-current conditions associated with BMD loss
Recommendations for pediatric patients
DXA is performed in patients aged C5 years with scans of the lumbar vertebrae (L1–L4) and TBLH; measurement of
BMD at the femur is not recommended. Results are interpreted with the Z-score
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vertebral or femoral sites), a different skeletal
site may be used, such as the distal third of the
radius in the non-dominant arm. The minimum
age for densitometric examinations is 5 years.
Regarding methodological variability and
the accuracy of measurements, the precision
error and least significant change (LSC)
detectable must be determined for each DXA
apparatus, independently from the information
provided by the manufacturer. Strict adherence
to protocols is required to obtain accurate
results. For complete instructions, refer to
appendix II of the International Society for
Clinical Densitometry (ISCD) 2013 position
document [20]. Equipment accuracy must be
assessed on a representative sample of patients
at any clinic. To analyze precision, 3
measurements must be performed on each of
at least 15 patients or 2 measurements on 30
patients, repositioning the patient after each
scan. The minimum acceptable precision varies
depending on the anatomical site evaluated, in
particular, for the lumbar spine it is 9%,
corresponding to an LSC of 5.3%. This margin
of error should be taken into account for
repeated measurements performed to assess
the effectiveness of drug treatment. For
example, a 4% variation in BMD of the lumbar
spine after a year of therapy would be below the
LSC for this segment (5.3%). Therefore, the
increase in density would not be attributable
with certainty to a pharmacological effect.
Serial evaluations should consider not only the
Z-score (or T-score) and BMD but also the BMC
and the area.
Frequency of DXA Follow-Up Current
recommendations indicate that DXA should
be performed at baseline and after
12–24 months in untreated patients with GD
and in those who have reached therapeutic
Table 2 Key points for the use of MRI to assess bone
marrow inﬁltration (BMI) in the diagnosis and follow-up
of patients with GD
Procedure and interpretation
T1-weighted MRI can measure the marrow fat
component; sequences of the femur and spine are used
for the quantiﬁcation of bone marrow inﬁltration
T2-weighted sequences are used to identify bone
infarcts, osteonecrosis, and the differential diagnosis of
bone crises. Evaluation of avascular osteonecrosis
requires T2-weighted MRI sequences and short-tau
inversion recovery (STIR)
The same semi-quantitative assessment method should
be used at baseline and follow-up
Frequency
Current recommendations indicate that MRI should be
performed at baseline and repeated every
12–24 months in treated patients with normal scores
24–36 months in untreated patients with normalized
scores
12 months in patients with severe bone marrow
burden (BMB) scores
24 months for patients with moderate BMB scores
Time dosage is adjusted when signiﬁcant complications
occur
However, we suggest that follow-up may be performed
every
12 months if the normalized score is[1
24 months if the normalized score is B1
36 months in stable patients with good metabolic
control and normalized scores consistently B1
Time dosage is adjusted, or signiﬁcant complications
occur
Recommendations for pediatric patients
Age-related bone marrow conversion in children
interferes with evaluation of inﬁltration; currently
there are no guidelines or standardized methods for
analyzing this parameter
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goals on ERT, whereas patients who have not
reached therapeutic goals should be assessed
every 12 months [17]. However, given the slow
rate of BMD changes we suggest that assessment
can be performed every 24–36 months in
untreated patients, and every 36 months in
patients who have achieved goals for skeletal
involvement on ERT. DXA should be repeated
at shorter intervals (e.g., 12–24 months) in
patients with conditions associated with a
rapid loss of bone mass (e.g., corticosteroids
therapy). The minimum time interval for
evaluating bone density during the course
of treatment is 6 months. Serial DXA
examinations should be performed using
the same device, possibly by the same operator
[23].
Magnetic Resonance Imaging (MRI) (Table 2)
Magnetic resonance imaging (MRI) is an
extremely sensitive method for monitoring
bone pathology in GD. Protocols include T1-
weighted spin echo and turbo sequences, short
tau inversion recovery (STIR) sequences, as well
as T2-weighted spin echo, turbo spin echo or
gradient echo sequences. Spin echo MRI
sequences are useful for identifying bone
marrow by its high fat content, which appears
as a hyperintense T1-weighted signal and
an intermediate-to-hyperintense T2-weighted
signal. Bone marrow infiltration (BMI) by
Gaucher cells displaces fatty marrow, resulting
in a less intense signal. Regression of BMI, for
example as a consequence of ERT, increases
marrow fat content and causes the signal
intensity to normalize. Some changes are
irreversible, such as bone infarction and fibrosis.
MRI is also the most sensitive method to
detect osteonecrosis. Increased signal intensity
in T1- and T2-weighted images or hyperintense
signal in STIR is suggestive of active bone
marrow events. STIR may reveal osteonecrosis
that is obscured by Gaucher cell infiltration in
T1-and T2-weighted images.
The age-related conversion of hematopoietic
to fatty bone marrow that occurs in children
interferes with evaluation of BMI, and currently
there are no guidelines or standardized methods
for analyzing this parameter. Therefore, in
clinical practice BMI is not assessed in
pediatric patients. However, MRI is useful for
assessing osteonecrosis and active bone marrow
events in pediatric patients.
MRI is a qualitative method, but semi-
quantitative methods have been developed to
assess BMI by Gaucher cells. BMI is clinical
relevant because it is an index of disease severity
and of the risk of bone crisis and osteonecrosis.
Semi-quantitative MRI methods compare signal
intensities to an internal reference standard.
Six semi-quantitative methods have been
developed that differ mainly by the body area
evaluated. These methods have been validated
by comparison to other methods, and inter-
rater reliability has been assessed at multiple
centers [24–29]. Of these, the bone marrow
burden (BMB) seems to be the most commonly
used method.
A quantitative MRI method known as
quantitative chemical shift imaging (QCSI) has
also been developed [30]. QCSI quantifies fat
content using differences in the resonant
frequencies of fat and water in bone marrow.
However, it is not universally available, relies on
specialist technical input, is time consuming, and
prone to both measurement errors and artifacts.
For all these reasons, it is not used in clinical
practice. BMI can be measured using scintigraphic
imaging with semi-quantitative assessment;
however, whereas it is widely available, this
method has low specificity, and physiological
excretion of markers hampers assessment of the
abdominal region. Recently, Di Rocco et al. [3]
have normalized these methods so that their
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results are now comparable, allowing clinicians
and radiologists to use any one of these methods
(Table 3).
Frequency of MRI Follow-Up The International
Registry Collaborative Gaucher Group (ICGG)
has developed recommendations for effective
monitoring of adult patients with GD type 1
[17]. These indicate that MRI should be
performed at diagnosis and then every
12–24 months for patients not receiving ERT
and for those who have not achieved
therapeutic goals while receiving ERT, whereas
patients who have achieved therapeutic goals
while receiving ERT should be monitored every
24–36 months. Assessments should be
performed also when changing therapy or in
the event of significant clinical complications.
Therapeutic goals for BMI have not been
established.
Follow-up imaging may be less frequent in
untreated patients with minimal disease who
lack evidence of progression over several years,
or in treated patients with negligible BMI
and evidence of stable disease. Conversely,
evaluations should be more frequent in
untreated symptomatic patients with
significant disease burden [17].
MRI is cost-effective in terms of diagnostic
value and the cost of therapy; however, it is
expensive and for this reason, we propose the
following protocol. At baseline, total body semi-
quantitative MRI should be used to check for
osteonecrosis in sites other than the femoral
head [31]. The same semi-quantitative method
should be used for follow-up. However, in our
opinion, total body MRI is not useful for follow-
up. Instead, we suggest performing MRI on
specific symptomatic regions.
If the baseline normalized score (see Table 2)
is B1, MRI should be performed every
24 months; if it is [1, MRI should be
performed every 12 months. In stable patients
with good metabolic control and scores
Table 3 Equivalence of disease severity scores for magnetic resonance and scintigraphic evaluation of bone marrow
involvement in patients with Gaucher disease
Normalized score Rosenthal Dusseldorf Terk VDR BMB
0 0 0 0 [2.0 0–2
1 1–3 1–3 1a,b 1.5–2.0 3–7
2 4–7 4–6 2a,b 1.0–1.5 8–12
3 8–11 7–8 3a,b \1.0 13–16
Normalized score QCSI fat fraction S-MRI 99mTc-sestamibi 99mTc-radiocolloid
0 [0.30 0–4 0–2 Normal
1 0.30–0.25 5–10 3–4 Mild
2 0.20–0.25 11–17 5–6 Moderate
3 \0.20 18–24 7–8 Severe
Reproduced with permission from [3]
a The presence of osteonecrosis is not considered in the bone marrow score per se, since it indicates involvement of the
bone mineral component rather than the marrow component, which is the primary focus of MRI
b Degree of impairment in the normal scintigraphic pattern. BMB bone marrow burden, S-MRI Spanish magnetic
resonance index, VDR vertebral disk ratio, QCSI quantitative chemical shift index
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consistently B1, MRI can be performed every
36 months.
Plain Radiography
Radiographic examination is widely available
and inexpensive, but it has low sensitivity in
detecting initial and small changes in skeletal
involvement in GD patients [7]. However, it is
useful for detecting bone complications such as
fractures. In addition, radiographic imaging
may reveal skeletal lesions, cortical bone
thinning, and Erlenmeyer flask deformation
that may lead to incidental diagnosis of GD in
asymptomatic patients.
The guideline developed by the
International Collaborative Gaucher Group
(ICGG) recommends that the initial
assessment include X-ray examination of the
femora, spine, and any other symptomatic sites,
but indicates that MRI provides much more
information on BMB [17]. Conventional
radiography may be useful for characterizing
osteonecrosis of the proximal femur and
osteosclerotic areas, when used in the context
of an appropriate classification system.
Steinberg has proposed a classification
system that we agreed is useful for identifying
progression of radiographic damage and
providing information to guide surgical
approaches (Steinberg et al. 1998). It is derived
from the system of Arlet and Ficat [32] and
includes additional stages (Table 4).
Biomarkers for Bone Damage
Bone manifestations commonly involve
decreases or increases in the rate of bone
turnover and imbalance between bone
resorption and formation. Bone turnover can
be measured with specific biochemical markers
Table 4 Steinberg (or University of Pennsylvania)
classiﬁcation system for avascular necrosis of the femoral
head
Stage Criteria
0 Normal or nondiagnostic radiograph, bone scan,
MRI
I Normal radiographs; abnormal bone scan and/or
MRI
A: Mild (\15% of femoral head affected)
B: Moderate (15–30%)
C: Severe ([30%)
II Cystic and sclerotic changes in femoral head
A: Mild (\15% of femoral head affected)
B: Moderate (15–30%)
C: Severe ([30%)
III Subchondral collapse (crescent sign) without
ﬂattening
A: Mild (\15% of articular surface)
B: Moderate (15–30%)
C: Severe ([30%)
IV Flattening of femoral head
A: Mild (\15% of surface and\2 mm
depression)
B: Moderate (15–30% of surface and 2–4 mm
depression)
C: Severe ([30% of surface and[4 mm
depression)
V Joint narrowing or acetabular changes
A: Milda
B: Moderatea
C: Severea
VI Advanced degenerative changes
a Mean femoral head involvement, as determined in stage
IV, and estimated acetabular involvement. MRI magnetic
resonance imaging. Reproduced with permission from [60]
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for enzyme activities, the release of various
structural components of bone, and proteins
involved in the processes of bone formation
(Table 5). Over the years, most of these
parameters have been tested in patients with
GD [33–40]. Urinary total hydroxyproline levels
are used to identify osteoclastic hyperactivity.
Stowens et al. [41] reported a reduction in urinary
hydroxyproline levels in about one-third of
patients with GD compared with controls,
suggesting a reduction in bone resorption in
these patients. Furthermore, osteoblast activity
also appears to be suppressed in patients with GD
not treated with replacement therapy, as
demonstrated by a threefold decrease in levels
of markers of osteoblast activity: osteocalcin [34]
and carboxy-terminal propeptide of procollagen
type 1 (P1NP) [35]. More recently, Van Dussen
et al [40]. reported a significant reduction in
osteocalcin levels, without significant changes in
levels of carboxy-terminal telopeptide of type I
collagen (CTX, a marker of osteoclast activity), in
50% of patients with GD type 1, suggesting that
the altered bone turnover is mainly characterized
by a reduction of bone formation. Moreover,
Mikosch et al. [38] had previously reported that
levels of tartrate-resistant acid phosphatase
(TRAP), a widely used osteoclast marker, are
unchanged in patients with GD.
Recently, a systematic review has
consolidated the view that there are many
contradictory results in the literature and that
currently there is no scientific evidence to
support the use of biochemical markers for the
early diagnosis or follow-up of bone
involvement in GD [42]. CTX and P1NP have
gained attention recently; however, there is not
sufficient evidence to warrant their use in
clinical practice. It is not clear that any of
these markers provide information on bone
involvement beyond that obtained with the
routinely measured indicators of bone
metabolism. Furthermore, biochemical markers
provide only an instantaneous measurement of
status, whereas imaging reflects the cumulative
effects of bone gain and loss throughout life.
Thus, we recommend periodic measurement of
serum calcium and phosphorus, bone
isoenzyme of alkaline phosphatase (BALP),
PTH, urinary calcium and phosphorus, and
25-hydroxyvitamin D. In addition, because
vitamin D deficiency is common, its status
should be determined and corrected if needed.
Enzyme Replacement Therapy
The availability of enzyme replacement therapy
(ERT) has significantly improved the treatment of
GD, making it possible to establish meaningful
therapeutic goals for skeletal manifestations of
GD (Table 6). Three recombinant mannose-
terminated forms of glucocerebrosidase are
available for ERT: imiglucerase [43] was
approved in 1994, velaglucerase alfa [44] was
approved in the US and Europe in 2010, and
taliglucerase alfa [45] was approved in the US and
Israel in 2012, and subsequently in Brazil, Chile,
and Mexico. Most of the data on skeletal
treatment goals come from studies conducted
with imiglucerase, which has been shown to
significantly improve all bone parameters
identified as therapy goals (Supplementary
Table 5 Biomarkers for bone damage
We suggest that the following markers be measured
every 12 months
Serum calcium and phosphorus
Urinary calcium and phosphorus
The bone isoenzyme of alkaline phosphatase (BALP)
Parathyroid hormone
25-Hydroxyvitamin D
In addition, vitamin D status should be determined and
corrected if deﬁcient
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Tables 1 and 2) and thus may prevent serious
skeletal complications such as bone collapse
and fractures. Moreover, post-marketing
pharmacosurveliance of more than 4,500
patients reveals that imiglucerase is associated
with a stable and low rate of adverse events [46].
ERT improves the visceral aspects of GD in
the first year, whereas skeletal involvement
requires a longer treatment period [10].
Improvements in bone marrow infiltration are
seen within the first 3 years of treatment with
ERT [25], and better results are achieved at
higher dosages [47]. A meta-analysis of clinical
studies evaluated the effects of ERT on bone
complications from GD, suggesting that the
bone marrow fat fraction increases significantly
following treatment and that 70% of adults
with GD respond to treatment [48]. ERT
increases the hyperintense T1-weighted MRI
signal in bone marrow and significantly
reduces BMB scores in patients with GD [28, 49].
On the other hand, normalization of BMD
requires long-term treatment for up to 8 years,
and there is a clear dose–response relationship
[11, 50]. Appropriate dosage is based on disease
severity and the risk of progression. Patients are
considered to have high-risk disease if they have
symptomatic skeletal involvement, significant
visceral or hematological involvement, or, in
the case of pediatric patients, if they exhibit
growth failure [51]. The patient in Case 2
(Supplement) had a low BMD for his age
(T-score -3.16) and had experienced a vertebral
collapse. BMD did not respond to initial low-dose
imiglucerase therapy; however, increasing the
dosage to 60 U/kg every 2 weeks was associated
with gradual normalization of BMD.
Data on 889 patients in the International
Collaborative Gaucher Group (ICGG) registry
revealed low BMD for chronological age among
patients in all age groups, with the highest
prevalence among adolescents [8]. ERT
improved bone mass in all age groups, but the
greatest effect was seen in younger subjects,
emphasizing that a therapeutic window of
opportunity exists and that high-dosage
therapy may have the greatest effect in
younger patients during the period when peak
bone mineral density is accrued. Starting ERT
sooner after diagnosis of GD is associated with
better outcomes for avascular necrosis [14] and
for bone outcomes in general [8]. However, ERT
is also effective at stabilizing or slowing the
progression of bone disease in adult patients
who are diagnosed or treated late and may not
have achieved peak bone density.
In patients with suboptimal bone responses
to ERT, differential diagnosis should exclude
other diseases that can mimic osteoporosis (e.g.,
osteomalacia, myelomatosis). It is very
important to continue ERT at an optimal
dosage in patients with poor or partial bone
responses while evaluating concomitant
conditions that may be driving bone mineral
loss, such as hyperthyroidism, Cushing
syndrome, hypogonadism, alcoholism,
glucocorticoid therapy, or vitamin D deficiency.
Table 6 Key points for enzyme replacement therapy for
bone manifestations
Enzyme replacement therapy (ERT) is the standard of
care for Gaucher disease (GD) types 1 and type 3
Dosage is individualized and based on disease severity
and the presence of additional risk factors for bone
disease progression
Bone manifestations require long-term treatment at
higher dosage to achieve a therapeutic effect
Patients with signiﬁcant skeletal involvement or other
risk factors should receive high-dose therapy (60 U/
kg/every 2 weeks)
Young patients should receive high-dose therapy to
promote attainment of adequate peak bone mineral
density during this critical period
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Other Therapies
Patients who cannot receive treatment with ERT
may benefit from substrate reduction therapy
(SRT), which reduces the accumulation of
glycosphingolipids by inhibiting the formation
of their glucosylceramide precursors. Miglustat
is a small molecule glucosylceramide synthase
inhibitor licensed for use in adults with mild to
moderate GD type 1. However, it is indicated as
second line therapy due to its lower efficacy and
tolerability [52, 53]. A second glucosylceramide
synthase inhibitor (eliglustat) has shown
statistically significant improvement in lumbar
spine BMD in phase II trials [54, 55] and was
recently approved in the US for use in adult
patients with GD type 1.
Supportive Therapies to ERT for Treatment
of Bone Manifestations in Gaucher Disease
Patients with bone mineral deficit may benefit
from anti-osteoporotic drugs, in addition to
specific therapy (ERT) for GD. The fracture risk
assessment tool (FRAX) from the World Health
Organization quantifies the 10-year fracture risk
from skeletal fragility due to primary
osteoporosis and identifies a therapeutic
threshold beyond which pharmacological
treatment is indicated (http://www.shef.ac.uk/
In normal 
range?
BMI score 
≤2?
Z-score
<-2.0?
Determine if ERT is 
indicated, based on 
haematological, visceral 
and skeletal involvement
Follow 
up
Follow 
up
Consider 
treatment
Diagnosis of Gaucher 
disease
• Beta-glucosidase acvity
• Mutaon analysis 
MRI DXA Bone biomarkers
YESNO NO NO
Haematological
assessment 
Visceral
assessment
Skeletal
assessment
Follow 
up
Determine personalised 
ERT  dosage
Consider an-
osteoporoc
therapy
Follow up
Inial 
evaluaon
YES YES
Bone biomarkers:
• serum calcium and phosphorus; 
• urinary calcium and phosphorus;
• bone isoenzyme of alkaline 
phosphatase, 
• Parathyroid hormone,
• 25-hydroxy vitamin D
*
* See table 3 for 
bone marrow 
inﬁltraon (BMI) 
score normalisaon
Fig. 1 Proposed algorithm for diagnosing and managing
bone manifestations in patients with Gaucher disease. BMI
Bone marrow inﬁltration, DXA dual energy X-ray
absorptiometry, ERT enzyme replacement therapy, MRI
magnetic resonance imaging
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FRAX/index.aspx). In young subjects, a marked
reduction in bone mass documented by DXA is
an indication for anti-osteoporotic drugs, par-
ticularly bisphosphonates. Treatment with
alendronate 40 mg/day provided a significant
improvement in BMD at the lumbar spine in
patients with GD [56]. Administration of bis-
phosphonates in GD is supported by guidelines
from several scientific societies, though not as
preventive therapy [57].
Algorithm for Diagnosis and Follow-Up of Bone
Disease in Gaucher Disease Type 1
The flow charts in Figs. 1 and 2 show proposed
algorithms for managing bone disease in GD
type 1, based on the information and discussion
in the preceding sections. Figure 1 depicts
initial steps for diagnosis and treatment of
patients, while Fig. 2 shows steps in
monitoring for and follow-up of bone
involvement.
CONCLUSION
The severity of skeletal involvement in type 1
GD is variable, but associated with significant
pain, disability, and reduced QoL; thus, all
patients should be monitored regularly for the
onset and progression of skeletal pathology.
DXA is the method of choice for measuring
normal 
range?BMI score ≤1 
Z-score
<-2.0?
Re-assess ERT dosage; 
increase if appropriate 
Repeat 
aer 12 
months 
Consider 
treatment
MRI DXA Bone biomarkers
YES NO YES NO YES NO
Bone biomarkers:
• serum calcium and phosphorus; 
• urinary calcium and 
phosphorus;
• bone isoenzyme of alkaline 
phosphatase, 
• Parathyroid hormone,
• 25-hydroxy vitamin D
Consider an-
osteoporoc
therapy
Follow up of bone 
involvement in GD
Repeat 
aer 
24-36 
months **
ERT?
YES NO
* See table 3 for 
bone marrow 
inﬁltraon (BMI) 
score normalisaon
**More frequent in 
paent with higher 
disease severity 
score on  GauSSI-I 
Repeat 
aer 
12-24 
months **
Repeat 
aer 
12 months
Repeat 
aer 
24 months
Severe
?
YES NO
Repeat aer
12 months
Stable, BMI 
score ≤1?
YES NO
Repeat aer 
12 months
Repeat aer 
12-24 months;
36 months if 
all therapeuc 
goals are 
achieved 
Repeat aer
24 months
*
*
Fig. 2 Proposed algorithm for monitoring, and follow-up
of bone involvement in patients with Gaucher disease. BMI
Bone marrow inﬁltration, DXA dual energy X-ray
absorptiometry, ERT enzyme replacement therapy,
GauSSI-I Gaucher disease Severity Score Index-type I,
GD Gaucher disease, MRI magnetic resonance imaging
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BMD, whereas MRI is the method of choice for
evaluating bone marrow infiltration. Correct
performance and interpretation of these
methods are paramount to obtaining clinically
useful information.
ERT has changed the fate of patients with a
diagnosis of GD, as demonstrated in numerous
clinical studies. Continuous, long-term ERT
should be considered for all patients with
progressive skeletal involvement and those at
risk of developing severe skeletal complications,
including children with symptomatic GD. Early
treatment at the appropriate individualized
dosage is crucial for preventing irreversible
skeletal damage. The dosage for individual
patients is based on disease severity and
response to therapy. Patients at high risk of
skeletal disease should receive ERT at a dosage
of 60 U/kg/2 weeks. Anti-osteoporotic therapy
should be administered in addition to ERT
when indicated.
Looking to the future, therapies combining
ERT with SRT have the potential to provide
further benefits [58]; however, a small
24-month controlled study did not show a
significant benefit for combination therapy
with imiglucerase plus miglustat, compared to
either drug in monotherapy [59]. Combination
therapies should continue to be investigated
thoroughly as new agents emerge.
Skeletal manifestations of GD are not
necessarily intractable, and patients who are
diagnosed and treated early, before
irreversible damage occurs, are spared from
severe bone involvement. Registry data show
that for most adults with late-diagnosed bone
involvement, the onset of GD was in
childhood. Thus, every effort must be made
to monitor for skeletal involvement starting
in pediatric patients.
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